“…Consistent with this, therapies blocking Ang II activity such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) effectively lower blood pressure, reduce risk for diabetes, prevent deficits in cardiovascular and metabolic functions and increase lifespan in aged animals and clinical populations [ 7 , 9 , 10 , 11 ]. Of interest, ACE inhibitors and ARBs increase levels of the protective hormone Ang-(1-7), which our group and others have shown contributes to the beneficial cardiometabolic effects of these therapies in animal models of cardiovascular diseases, obesity, and diabetes [ 12 , 13 , 14 , 15 ]. Importantly, ACE inhibitors are limited in up to 11% of patients by cough due to production of kinins, and many patients are unresponsive to these therapies in terms of blood pressure control [ 16 ].…”